Champions Oncology: annual meeting voting results

What happened

• Champions Oncology, Inc. reported that on Oct 14, 2026, at its Annual Meeting of Stockholders the seven director nominees named in the Company's 2026 proxy statement were elected to serve one-year terms expiring at the 2027 Annual Meeting.
• The filing also reported that stockholders ratified the appointment of EisnerAmper LLP as the Company’s independent registered public accounting firm, approved a non-binding advisory resolution on the compensation of the Company's named executive officers, recommended annual advisory votes on compensation, and approved the 2026 Equity Incentive Plan.

Key details

• Director election vote totals (Votes For / Votes Withheld / Broker non-vote): Robert Brainin 7,904,120 / 338,790 / 461,706; Ronnie Morris, M.D. 7,883,105 / 359,805 / 461,706; Joel Ackerman 7,549,214 / 693,696 / 461,706; David Sidransky, M.D. 7,154,225 / 1,088,685 / 461,706; Daniel Mendelson 7,904,471 / 338,439 / 461,706; Scott R. Tobin 8,230,372 / 12,538 / 461,706; Brian Alexander, M.D. 8,241,264 / 1,646 / 461,706.
• Ratification of independent registered public accounting firm (EisnerAmper LLP): Votes For 8,702,771; Votes Against 1,845; Abstain 0.
• Non-binding advisory votes on executive compensation and frequency: approval of named executive officer compensation—Votes For 7,130,832; Votes Against 25,242; Abstain 1,086,836; Broker non-vote 461,706. Frequency vote—1 Year 7,198,608; 2 Years 38,035; 3 Years 1,003,655; Abstain 2,612; Broker non-vote 461,706. The Company intends to hold future advisory votes on executive compensation annually.
• Approval of the 2026 Equity Incentive Plan: Votes For 6,401,638; Votes Against 754,480; Abstain 1,086,792; Broker non-vote 461,706.

Why it may matter

• The filing reports Item 5.07 (submission of matters to a vote of security holders), covering director elections, ratification of the independent auditor, advisory votes on executive compensation and the frequency of those votes, and approval of the 2026 Equity Incentive Plan.
• This filing does not show why the insider traded or why the company acted.